Corpus ID: 21832757

A placebo-controlled trial of the immune modulator, lentinan, in HIV-positive patients: a phase I/II trial.

@article{Gordon1998APT,
  title={A placebo-controlled trial of the immune modulator, lentinan, in HIV-positive patients: a phase I/II trial.},
  author={M. Gordon and B. Bihari and E. Goosby and R. Gorter and M. Greco and M. Guralnik and T. Mimura and V. Rudinicki and R. Wong and Y. Kaneko},
  journal={Journal of medicine},
  year={1998},
  volume={29 5-6},
  pages={
          305-30
        }
}
Lentinan is a beta 1-->3 glucan isolated from Lentinus edodes (Shiitake mushroom) which has immune modulating properties. We have conducted two phase I/II placebo-controlled trials on a total of 98 patients. In one study at the San Francisco General Hospital (SFGH), ten patients each were administered 2, 5, or 10 mg of lentinan or placebo i.v. once a week for eight weeks. In the second study at the Community Research Initiative in New York (CRI), two groups of 20 patients each were administered… Expand
Lentinan as an immunotherapeutic for treating lung cancer: a review of 12 years clinical studies in China
Immune modulating effects of β-glucan
Fighting infection using immunomodulatory agents
  • K. Masihi
  • Biology, Medicine
  • Expert opinion on biological therapy
  • 2001
Shiitake mushroom dermatitis.
Severe urticaria due to recombinant interferon beta‐1a
Potential of the β-glucans to enhance innate resistance to biological agents
...
1
2
3
4
5
...